Page 15 - CIRN-AR-2015-PRESS.indd
P. 15
From April 2014 to March 2015
CIRN represents over SERIOUS CIRN members and investigators published and
130 investigators and contributors OUTCOMES presented (abstracts or orals))
and continues to grow SURVEILLANCE 47 times
its network of experts NETWORK
CANADIAN CLINICAL TRIALS
NATIONAL VACCINE SOS CTN SIC PCN CANVAS NETWORK
SAFETY NETWORK
O R E I N F R A S T R U C T U
C R
E
5 S
Year 2 project proposals initiated
CIRN will continue PCIRN’s legacy 19 submissions for
and operate as a “network of
networks” through review, out of which
15 moved ontomoved onto
15
5 core infrastructures the peer-review
& 3 supporting pp g process
infrastructures
SPECIAL
IMMUNIZATION
PROVINCIAL CLINIC NETWORK
COLLABORATIVE
NETWORK 3 S U P P O R T I N G I N F R A S T R U C T U R E S
SSHN RLN ModERN
Like PCIRN, CIRN was also
MODELING AND launched through a
SOCIAL SCIENCES ECONOMICS
AND HUMANITIES RESEARCH 3-year grant
NETWORK REFERENCE NETWORK of $6.6 million
LABORATORY
NETWORK
CLINICAL TRIALS CANADIAN SERIOUS OUTCOMES PROVINCIAL SPECIAL
NETWORK NATIONAL VACCINE SURVEILLANCE COLLABORATIVE IMMUNIZATION
• Clinical trials: early phase, late SAFETY NETWORK NETWORK NETWORK CLINIC NETWORK
phase, rapid trials • Vaccine safety immediately • Provides hospital based • Develops common analytic • Standardized clinical
• For specialized groups: after implementation of surveillance, test-negative methodologies to assess assessment of AEFI
elderly, aboriginal, pediatric, annual infl uenza vaccine case control methods studies, vaccine safety, eff ectiveness, • Safety of re-immunization
adult campaigns rapid response to emerging and coverage, including • Special & at-risk populations
vaccine safety signals along
the use of both aggregate
• Across 6 Provinces & 10 Sites • Safety of other vaccines used with IMPACT) across full age and linkable individual-
in these cohorts, evaluation spectrum level, large, highly powered • Across 6 Provinces & 10 Sites
of vaccine hesitancy, and datasets available to
vaccine eff ectiveness • Across 7 Provinces & 45 Sites provinces
• 8 Sites across Canada (28% of country’s adult acute-
care beds)
3 SUPPORTING INFRASTRUCTURES
SOCIAL SCIENCES AND HUMANITIES REFERENCE LABORATORY NETWORK MODELING AND ECONOMICS RESEARCH
NETWORK • Across 3 provinces & 5 sites NETWORK
• Linking social scientists and humanities researchers across • Together with iCARE network, RLN provides a national • Epidemiological analyses
Canada to examine ethical, legal, and social implications sero-epidemiology network • Mathematical modeling
of vaccine programs
• Strong focus in the area of Vaccine Hesitancy • Manages sample archive or sera & other biological • Economics analyses
samples for future studies
• Across 5 Provinces
•
CIRN represents over SERIOUS CIRN members and investigators published and
130 investigators and contributors OUTCOMES presented (abstracts or orals))
and continues to grow SURVEILLANCE 47 times
its network of experts NETWORK
CANADIAN CLINICAL TRIALS
NATIONAL VACCINE SOS CTN SIC PCN CANVAS NETWORK
SAFETY NETWORK
O R E I N F R A S T R U C T U
C R
E
5 S
Year 2 project proposals initiated
CIRN will continue PCIRN’s legacy 19 submissions for
and operate as a “network of
networks” through review, out of which
15 moved ontomoved onto
15
5 core infrastructures the peer-review
& 3 supporting pp g process
infrastructures
SPECIAL
IMMUNIZATION
PROVINCIAL CLINIC NETWORK
COLLABORATIVE
NETWORK 3 S U P P O R T I N G I N F R A S T R U C T U R E S
SSHN RLN ModERN
Like PCIRN, CIRN was also
MODELING AND launched through a
SOCIAL SCIENCES ECONOMICS
AND HUMANITIES RESEARCH 3-year grant
NETWORK REFERENCE NETWORK of $6.6 million
LABORATORY
NETWORK
CLINICAL TRIALS CANADIAN SERIOUS OUTCOMES PROVINCIAL SPECIAL
NETWORK NATIONAL VACCINE SURVEILLANCE COLLABORATIVE IMMUNIZATION
• Clinical trials: early phase, late SAFETY NETWORK NETWORK NETWORK CLINIC NETWORK
phase, rapid trials • Vaccine safety immediately • Provides hospital based • Develops common analytic • Standardized clinical
• For specialized groups: after implementation of surveillance, test-negative methodologies to assess assessment of AEFI
elderly, aboriginal, pediatric, annual infl uenza vaccine case control methods studies, vaccine safety, eff ectiveness, • Safety of re-immunization
adult campaigns rapid response to emerging and coverage, including • Special & at-risk populations
vaccine safety signals along
the use of both aggregate
• Across 6 Provinces & 10 Sites • Safety of other vaccines used with IMPACT) across full age and linkable individual-
in these cohorts, evaluation spectrum level, large, highly powered • Across 6 Provinces & 10 Sites
of vaccine hesitancy, and datasets available to
vaccine eff ectiveness • Across 7 Provinces & 45 Sites provinces
• 8 Sites across Canada (28% of country’s adult acute-
care beds)
3 SUPPORTING INFRASTRUCTURES
SOCIAL SCIENCES AND HUMANITIES REFERENCE LABORATORY NETWORK MODELING AND ECONOMICS RESEARCH
NETWORK • Across 3 provinces & 5 sites NETWORK
• Linking social scientists and humanities researchers across • Together with iCARE network, RLN provides a national • Epidemiological analyses
Canada to examine ethical, legal, and social implications sero-epidemiology network • Mathematical modeling
of vaccine programs
• Strong focus in the area of Vaccine Hesitancy • Manages sample archive or sera & other biological • Economics analyses
samples for future studies
• Across 5 Provinces
•
